IBT
BIIB icon

International Biotechnology Trust’s Biogen BIIB Stock Holding History

International Biotechnology Trust’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$10.3M Buy
40,200
+29,200
+265% +$7.81M 3.48% 8
2023
Q2 		$3.13M Sell
11,000
-10,400
-49% -$3.1M 0.95% 32
2023
Q1 		$5.95M Hold
21,400
– – 1.66% 21
2022
Q4 		$5.92M Sell
21,400
-24,100
-53% -$6.81M 1.83% 19
2022
Q3 		$12.1M Buy
45,500
+34,894
+329% +$7.41M 3.9% 6
2022
Q2 		$52K Buy
+10,606
New +$2.17M 0.54% 40
2022
Q1 		– Sell
-47,500
Closed -$11.4M – 73
2021
Q4 		$11.4M Buy
47,500
+22,000
+86% +$5.66M 2.54% 14
2021
Q3 		$7.21M Sell
25,500
-23,000
-47% -$7.54M 1.74% 19
2021
Q2 		$16.8M Hold
48,500
– – 4.43% 9
2021
Q1 		$13.6M Buy
48,500
+15,700
+48% +$4.23M 3.59% 12
2020
Q4 		$8.02M Sell
32,800
-10,800
-25% -$2.79M 2.19% 17
2020
Q3 		$12.3M Sell
43,600
-7,600
-15% -$2.12M 3.99% 10
2020
Q2 		$13.3M Buy
51,200
+5,500
+12% +$1.65M 4.43% 8
2020
Q1 		$14.5M Hold
45,700
– – 6.59% 3
2019
Q4 		$13.6M Buy
45,700
+14,000
+44% +$3.88M 4.88% 7
2019
Q3 		$7.38M Sell
31,700
-11,000
-26% -$2.56M 3.41% 11
2019
Q2 		$9.98M Buy
42,700
+33,200
+349% +$7.67M 3.7% 9
2019
Q1 		$2.25M Sell
9,500
-7,700
-45% -$2.42M 0.83% 36
2018
Q4 		$4.06M Buy
+17,200
New +$5.49M 2.52% 15
2018
Q3 		– Sell
-36,208
Closed -$10.5M – 52
2018
Q2 		$10.5M Sell
36,208
-9,400
-21% -$2.64M 4.04% 7
2018
Q1 		$12.5M Sell
45,608
-19,400
-30% -$6.02M 4.87% 5
2017
Q4 		$20.7M Sell
65,008
-6,500
-9% -$2.09M 7.3% 1
2017
Q3 		$22.4M Buy
71,508
+10,400
+17% +$3.08M 8.71% 2
2017
Q2 		$16.6M Sell
61,108
-14,300
-19% -$3.78M 6.3% 4
2017
Q1 		$20.6M Buy
75,408
+9,500
+14% +$2.69M 7.89% 2
2016
Q4 		$18.7M Buy
+65,908
New +$19.5M 8.42% 2

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

International Biotechnology Trust's BIIB Position: Q3 2023 in Review

International Biotechnology Trust increased its Biogen (BIIB) stake by 265% in Q3 2023, buying an estimated $7.81M and bringing the position to 40,200 shares worth $10.3M. The position accounts for 3.48% of the portfolio, ranked #8.

International Biotechnology Trust first reported a position in BIIB in Q4 2016 and has held it in 26 quarters since. The position peaked at $22.4M in Q3 2017. 966 funds tracked by Wall St. Rank hold BIIB as of Q3 2023.

  • International Biotechnology Trust held 40,200 shares of Biogen worth $10.3M as of Q3 2023.
  • International Biotechnology Trust bought 29,200 Biogen shares in Q3 2023, an estimated $7.81M.
  • Biogen made up 3.48% of International Biotechnology Trust's portfolio in Q3 2023, its #8 holding.
  • International Biotechnology Trust first reported a position in Biogen in Q4 2016 and has held it in 26 quarters since.
  • International Biotechnology Trust's Biogen position peaked at $22.4M in Q3 2017.
  • 966 funds tracked by Wall St. Rank held Biogen as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.